Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 9Unknown 4Terminated 2Recruiting 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcopenia 1Postoperative Complications 1Polycystic Ovary Syndrome 1Muscle Weakness 1Motor Activity 1Insulin Resistance 1Esophageal Neoplasms 1Body Weight 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Caloric Restriction × Clear all
NCT03676478 2025-12-10

EFECTS

University Hospital, Gasthuisberg

Phase NA Terminated
239 enrolled
Gastrointestinal

Esophageal Neoplasms, Postoperative Complications, Muscle Weakness, Sarcopenia

NCT01482286 2022-03-15

PULSE

Pennington Biomedical Research Center

Phase 3 Terminated
32 enrolled 10 charts

Body Weight, Insulin Resistance, Motor Activity, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡